广州洁特生物过滤股份有限公司 2025年第三季度报告

Core Viewpoint - The company, Guangzhou Jiete Biological Filtration Co., Ltd., is actively involved in legal disputes and has made significant investments in a new industrial fund aimed at enhancing its strategic development and capital cooperation in the biopharmaceutical sector [6][10]. Financial Data - The financial report for the third quarter indicates that the financial statements have not been audited [3][8]. - The company has reported significant legal disputes involving its subsidiaries, which may impact its financial standing [6][7]. Legal Disputes - A subsidiary, Baifeier, has filed a lawsuit against Shanghai Deyou Electronic Technology Co., Ltd. for a contract dispute involving a total amount of approximately 18.44 million yuan, with a breach penalty of 1.39 million yuan [6]. - The court ruled in favor of Baifeier in the first instance, ordering the return of 18.44 million yuan and a penalty of approximately 922,084.59 yuan, but the defendant has appealed [6]. - Another dispute with Shenzhen Hesheng Medical Technology Co., Ltd. involves a claim of approximately 10.34 million yuan, with the court initially ruling in favor of the company, but the case is currently under appeal [7]. Investment Activities - The company has initiated the establishment of an industrial fund, Guangzhou Zengcheng Nante Biopharmaceutical Investment Partnership, with a total investment of 50.01 million yuan, where the company contributes 25 million yuan, representing 49.99% of the total [10][11]. - The fund aims to invest in early to mid-stage biopharmaceutical projects, enhancing the company's strategic development and capital cooperation [10]. Fund Registration - The fund has completed registration with the China Securities Investment Fund Industry Association and has received the private investment fund registration certificate on October 29, 2025 [12].